Core Viewpoint - A securities class action lawsuit has been filed against Lineage, Inc. for alleged material misrepresentations in its IPO Registration Statement, impacting investors who purchased shares during the IPO [1][6]. Allegations - The lawsuit claims that Lineage misrepresented the state of its business and industry trends in its IPO Registration Statement, which was declared effective on July 24, 2024 [6]. - It is alleged that the company falsely claimed that COVID-19 had accelerated growth in cold storage demand, which would benefit the company in the long term [6]. - The lawsuit also states that Lineage concealed a sustained downturn in its business, including destocking by customers and a market-wide shift towards leaner inventories [6]. - Additionally, the increase in overall cold storage supply negatively impacted occupancy rates and pricing power, particularly as Lineage had implemented unsustainable price hikes [6]. Impact on Investors - Investors have until September 30, 2025, to seek appointment as lead plaintiff in the case [3]. Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, a law firm with over 125 years of experience in securities litigation, is representing the investors in this case [4].

Core Viewpoint - The complaint against Sarepta Therapeutics alleges violations of federal securities laws due to misleading statements regarding the safety and efficacy of its treatment ELEVIDYS, which has been linked to patient deaths and regulatory scrutiny [2]. Group 1: Safety Concerns and Regulatory Actions - ELEVIDYS is reported to pose significant safety risks, with trial protocols failing to detect severe side effects [2] - Following a patient death on March 18, 2025, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3] - On April 4, 2025, Sarepta halted recruitment and dosing in some clinical studies after EU authorities requested a review of the death, leading to a further stock price decline of $4.18, or 7.13%, to $54.43 [4] - A second patient death due to acute liver failure was disclosed on June 15, 2025, prompting Sarepta to suspend shipments for non-ambulatory patients and pause dosing in one study [5] - Following the second death, Sarepta's stock fell by $15.24, or 42.12%, closing at $20.91 [6] - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into the deaths and acute liver failure risks associated with ELEVIDYS, resulting in a stock price drop of $1.52, or 8.01%, to $17.46 [6][7] Group 2: Legal Proceedings and Class Action - The lead plaintiff in the class action is the investor with the largest financial interest, who will oversee the litigation on behalf of the class [8] - Members of the putative class can choose to serve as lead plaintiff or remain absent without affecting their ability to share in any recovery [8] - Faruqi & Faruqi, LLP encourages individuals with information regarding Sarepta's conduct to come forward, including whistleblowers and former employees [9]

Core Viewpoint - Lockheed Martin has faced significant financial losses due to internal control failures and operational challenges, leading to a series of negative announcements that have impacted its stock price and investor confidence [2][3][4]. Financial Performance - On October 22, 2024, Lockheed Martin announced a loss of $80 million related to a classified program, resulting in a 6.12% drop in share price to $576.98 [3][5]. - On January 28, 2025, the company reported pre-tax losses of $1.7 billion, with $555 million attributed to the Aeronautics program and $1.3 billion to the Missiles and Fire Control business, leading to a net earnings drop from $6.9 billion in 2023 to $5.3 billion in 2024 [4][5]. - On July 22, 2025, an additional $1.6 billion in pre-tax losses was disclosed, including $950 million from the Aeronautics Classified program, resulting in a further decline in net earnings to $342 million [6][7]. Stock Market Reaction - Following the October 2024 announcement, Lockheed Martin's share price fell by $37.63 [3][5]. - The January 2025 announcement led to a $46.24 drop in share price [4][5]. - The July 2025 announcement resulted in a $49.79 decline in share price [6][7]. Legal Implications - A class action lawsuit has been initiated against Lockheed Martin, alleging violations of federal securities laws due to misleading statements and failure to disclose critical operational issues [2][8]. - The lead plaintiff in the lawsuit is an investor with the largest financial interest in the case, representing the interests of the class [8]. Company Operations - The complaints highlight that Lockheed Martin lacked effective internal controls and procedures for managing program complexities and risks, which contributed to the financial losses [2]. - The company has faced challenges in delivering on contract commitments regarding cost, quality, and schedule, leading to significant operational setbacks [2].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the withdrawal of its 2025 guidance [2][3]. Group 1: Allegations and Impact - Defendants allegedly made overwhelmingly positive statements while concealing adverse facts about Centene's true enrollment and morbidity rates [2] - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [2] - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% [3] Group 2: Legal Proceedings - The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [4] - Any member of the putative class can move to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [4] Group 3: Call for Information - Faruqi & Faruqi, LLP is encouraging individuals with information regarding Centene's conduct, including whistleblowers and former employees, to come forward [5]

Core Viewpoint - The complaint alleges that Capricor and its executives violated federal securities laws by making false or misleading statements regarding the drug deramiocel, which is intended for treating cardiomyopathy associated with Duchenne muscular dystrophy (DMD) [2] Group 1: Company Conduct - Capricor allegedly provided investors with overly positive statements about its ability to obtain a Biologics License Application (BLA) from the FDA while concealing adverse facts related to the safety and efficacy data from its Phase 2 HOPE-2 trial [2] - On July 11, 2025, Capricor received a Complete Response Letter (CRL) from the FDA, denying the BLA due to insufficient evidence of effectiveness and the need for additional clinical data [3] Group 2: Market Reaction - Following the announcement of the CRL, Capricor's stock price fell from $11.40 per share on July 10, 2025, to $7.64 per share on July 11, 2025, reflecting a significant decline in investor confidence [4]

Core Viewpoint - A securities class action lawsuit has been filed against Lineage, Inc. for alleged material misrepresentations in its IPO registration statement, impacting investors who purchased shares during the IPO [1][7]. Allegations Against Lineage, Inc. - The lawsuit claims that Lineage's Registration Statement for its IPO, effective on July 24, 2024, contained significant misrepresentations regarding the company's business state and industry trends [7]. - It is alleged that Lineage falsely claimed that COVID-19 had accelerated growth in cold storage demand, which would benefit the company in the long term [7]. - The company reportedly concealed ongoing business challenges, including: - Customers destocking inventory that was built during the pandemic [7]. - A market-wide shift towards maintaining leaner inventories [7]. - Increased overall cold storage supply affecting occupancy rates and pricing power, particularly due to unsustainable price hikes imposed by Lineage [7]. Impact on Investors - Investors have a legal deadline until September 30, 2025, to seek appointment as lead plaintiff in the case [3].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Fiserv To Contact Him Directly To Discuss Their Options The market began to learn the truth about Defendants' fraud on April 24, 2025. On that date, Fiserv shocked investors by reporting Clover GPV growth of only 8 percent for the first quarter of 2025, a material stepdown from 2024 GPV rates of between 14 and 17 percent. The Company attributed this slowing growth to lower 202 ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lockheed Martin To Contact Him Directly To Discuss Their Options As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose (1) that Lockheed Martin lacked effective internal controls regarding its purportedly risk adjusted contracts including the reportin ...

Core Viewpoint - A class action lawsuit has been filed against Sable Offshore Corp. for allegedly making false statements regarding its oil production activities, leading to investor damages during the specified class period [1][2]. Group 1: Lawsuit Details - The lawsuit was filed on behalf of purchasers of Sable Offshore Corp. securities between May 19, 2025, and June 3, 2025, and/or related to the company's secondary public offering on May 21, 2025 [1]. - Defendants allegedly misrepresented that Sable Offshore Corp. had restarted oil production off the coast of California when it had not, resulting in materially false and misleading statements about the company's business and prospects [2]. Group 2: Legal Representation - Wolf Haldenstein Adler Freeman & Herz LLP, a law firm with over 125 years of experience in securities litigation, is representing the investors in this case [4]. - The firm encourages affected investors to contact them for assistance and to join the lawsuit [5].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly misleading investors regarding the risks associated with its cow's milk-based formula, Enfamil, which is linked to a serious health risk in premature infants [1][4]. Group 1: Lawsuit Details - The class action lawsuit is filed in the United States District Court for the Southern District of New York on behalf of investors who purchased Reckitt securities between January 13, 2021, and July 28, 2024 [1]. - Investors have until August 4, 2025, to apply to the Court to be appointed as lead plaintiff in the lawsuit [1]. - The lawsuit claims that Reckitt failed to adequately warn about the increased risk of necrotizing enterocolitis (NEC) in premature infants consuming its formula [3][4]. Group 2: Allegations Against Reckitt - The lawsuit alleges that Reckitt made misleading statements and omissions regarding its business, financial condition, and prospects during the class period [4]. - Specific allegations include failing to disclose the risks associated with Enfamil, the potential impact on sales, and the exposure to legal claims [4]. - As a result of these omissions, Reckitt's positive statements about its business were deemed materially false and misleading [4]. Group 3: Company Background - Reckitt is a UK-based global consumer goods company facing over 500 product liability lawsuits related to its infant formula [3]. - The lawsuits claim that Reckitt and its competitor Abbott Laboratories did not adequately warn about the risks associated with their cow milk-based formulas [3]. Group 4: Legal Representation - Bragar Eagel & Squire, P.C. is representing the investors in this class action lawsuit and encourages affected individuals to reach out for more information [1][5]. - The firm specializes in representing individual and institutional investors in complex litigation [6].